Over two dozen studies demonstrated sterling results at clinics and at home with zero major adverse event reports. D’OXYVA® (deoxyhemoglobin vasodilator) has recorded significant results, delivering major clinical outcomes for well over 90% of users.
Average results rounded for display, based on number of enrolled subjects in each study with D’OXYVA® and user feedback.
Ask your doctor before taking D’OXYVA®.
✔ vasodilation and vasoconstriction in the vessels
✔catalyzing vessel structure growth (angiogenesis)
✔ auto-regulation of local blood supply in tissues and organs
✔ neuro-receptor signaling in the brain
✔ balancing blood pH, blood sugar, and other critical functions
Circularity Healthcare has been assembling a world-class scientific advisory board (partial list) that includes domestic and international medical thought-leaders in the field of diabetic relief, amputation prevention, micro-vascular physiology, neurology, endocrinology, vascular surgery, cardiovascular physiology, exercise science and others.
D’OXYVA® has demonstrated an exceptional efficacy and safety profile in quality human pivotal clinical studies including placebo-controlled double-blind, randomized trials and has been investigated at prestigious institutions around the world such as Penn State University, Florida State University, Valley Presbyterian Hospital, Hospital Kuala Lumpur, Airlangga University, Chulalongkorn University, University of Szeged, National Taipei University and others. Currently, its diabetic foot ulcer closure human pivotal trials are expanding to over a dozen top U.S. universities conducted by influential medical experts who are regularly called upon to testify in front of the U.S. Food and Drug Administration (FDA).
Improved oxygen-rich microcirculatory tissue perfusion is widely reported in published research to improve physiological processes that lead to significant health benefits and outcomes. These include, but are not limited to chronic, burn, trauma wound and tissue improvement and repair, boosting athletic performance, stamina, sleep quality, fading the appearance of spider and varicose veins, while aiding in skin health, and much more.
D’OXYVA has recorded instant, outsized, and sustained improvements of the autonomic nervous system (ANS) in the brain, enhanced tissue perfusion and blood circulation in macro-, and microcirculation, chronic wound closure and balanced blood pressure in controlled human studies.
The D’OXYVA mechanical applicator is a handheld, non-invasive skin infusion technology. Therefore, it is a non-significant risk (NSR) device, according to FDA guidelines.
Please contact us if you would like participate as a subject or health professional in Circularity’s clinical study program called the Center of Excellence (COE) program.
PIVOTAL HUMAN STUDY TRIAL RESULTS SHOW EXCEPTIONAL BLOOD CIRCULATION & HEALTH OUTCOMES
✔ D’OXYVA® improved microcirculation (Skin Perfusion Pressure) in a statistically significant manner in 100% of subjects by about 15-100% from absolute baseline (median over 40%)
✔ Improvement in blood flow peaked uniformly within 1 hour after a single 5-minute delivery on their thumb, and subsequently lasted for over 4 hours
✔ 100% of enrolled subjects responded positively without adverse event reports after being monitored for a year after the study
Fill out the form and receive more detailed information about D’OXYVA’s outstanding results!
Reduce unwanted doctor visits, recommended and ranked top by experts!